

**13<sup>th</sup> ANRS HBV Cure Workshop Program**  
**25<sup>th</sup> & 26<sup>th</sup> March 2026, at Institut Lumière, Lyon, France**

**Wednesday, 25<sup>th</sup> March 2026**

**Joint opening and closing statements for RNH / HBV Cure Workshop 10:30 – 10:45**

Yazdan Yazdanpanah, Éloi Verrier & Fabien Zoulim

**Young investigator session 10:45 – 12:15**

Chairs: Jean-Michel Pawlotsky and Éloi Verrier

HBV cure and RNH joint session

**Keynote lecture: 12:15 – 12:45**

Chairs: Raymond Schinazi and Fabien Zoulim

*What are the knowledge gaps to cure HBV and HDV infections?*

Massimo Levrero, Lyon

**Lunch break (1:05')**

**Best Young Researcher Presentation Award 13:50**

**Viral genome persistence 14:00 – 14:50**

Chairs: Christine Neuveut and Guillaume Giraud

*Viral chromatin: the role of nucleosome occupancy in cccDNA transcription*

Robert Schwartz, New York

*Mapping the hepatic hepatitis B transcriptome and design of single-cell tissue transcriptomics*

Jane McKeating, Oxford

**Immunological determinants of viral persistence 14:50 – 15:40**

Chairs: Pierre Tonnerre and Hélène Strick-Marchand

*Beyond exhaustion: T cell adaptation in chronic HBV infection*

Maike Hofmann, Freiburg

*Tracking B cell immunity before functional cure: Insights from NA withdrawal and spontaneous HBsAg loss cohorts*

Lucy Cooper, London

**Break (20')**

**The liver reservoir of infection 16:00 – 17:15**

Chairs: Andres Roca and David Durantel

*Spatial single-cell omics: new insights into liver diseases.*

Bertram Bengsch, Freiburg

*Single-cell landscape of the myeloid cell adaptations during liver fibrosis*

Moritz Peiseler, Berlin

*Heterogeneity of HBV/HDV and immune response distribution in the liver*

Maëlle Locatelli, Barcelona

**End of day 17:30**



**13<sup>th</sup> ANRS HBV Cure Workshop Program**  
**25<sup>th</sup> & 26<sup>th</sup> March 2026, at Institut Lumière, Lyon, France**

**Thursday 26<sup>th</sup> March, 2026**

**Novel therapies – Translational studies 8:30 – 10:10**

Chairs: Patrick Soussan and Barbara Testoni

*Induction of HBV-specific immune responses in immunocompetent humanized mice*

Hélène Strick-Marchand, Paris

*Development of novel therapeutic vaccine candidates*

Anna Kosinska, Munich

*Gene and epigenome editing of HBV*

Anuj Kumar & Fabien Zoulim, Lyon

*New approach to target HDV with antisense oligonucleotides*

Julie Lucifora, Lyon

**Break (15')**

**Cohort studies 10:25 – 11:40**

Chairs: Vincent Thibault and Lucia Parlati

*Hepatocellular carcinoma risk in a real-life cohort of chronic hepatitis B*

Marc Bourlière, Marseille

*Immune profiling of patients with CHB and CHD*

Upkar Gill, London

*Artificial intelligence in cohort studies and clinical trials for CHB and CHD*

Anders Boyd, Bern

**Novel therapies – Progress in clinical development 11:40 – 12:55**

Chairs: Vincent Leroy and Hélène Fontaine

*Treatment endpoints to guide clinical development of novel therapies*

Jordan Feld, Toronto

*Advances in RNA interference development*

Man-Fung Yuen, Hong Kong

*An update on Bulevirtide and novel treatments for CHD*

Elisabetta Degasperri, Milan

**Farewell and buffet lunch**